These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

341 related items for PubMed ID: 16237395

  • 21. Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone).
    Vernaleken I, Fellows C, Janouschek H, Bröcheler A, Veselinovic T, Landvogt C, Boy C, Buchholz HG, Spreckelmeyer K, Bartenstein P, Cumming P, Hiemke C, Rösch F, Schäfer W, Wong DF, Gründer G.
    J Clin Psychopharmacol; 2008 Dec; 28(6):608-17. PubMed ID: 19011428
    [Abstract] [Full Text] [Related]

  • 22. A single photon emission computed tomography scan study of striatal dopamine D2 receptor binding with 123I-epidepride in patients with schizophrenia and controls.
    Tibbo P, Silverstone PH, McEwan AJ, Scott J, Joshua A, Golberg K.
    J Psychiatry Neurosci; 1997 Jan; 22(1):39-45. PubMed ID: 9002391
    [Abstract] [Full Text] [Related]

  • 23. α2-adrenergic drugs modulate the binding of [18F]fallypride to dopamine D2/3 receptors in striatum of living mouse.
    Rominger A, Mille E, Böning G, Wängler B, Josef Gildehaus F, Arszol C, Bartenstein P, Cumming P.
    Synapse; 2010 Aug; 64(8):654-7. PubMed ID: 20336625
    [Abstract] [Full Text] [Related]

  • 24. PET studies of D2-receptor binding in striatal and extrastriatal brain regions: Biochemical support in vivo for separate dopaminergic systems in humans.
    Cervenka S, Varrone A, Fransén E, Halldin C, Farde L.
    Synapse; 2010 Jun; 64(6):478-85. PubMed ID: 20175222
    [Abstract] [Full Text] [Related]

  • 25. Measuring dopamine neuromodulation in the thalamus: using [F-18]fallypride PET to study dopamine release during a spatial attention task.
    Christian BT, Lehrer DS, Shi B, Narayanan TK, Strohmeyer PS, Buchsbaum MS, Mantil JC.
    Neuroimage; 2006 May 15; 31(1):139-52. PubMed ID: 16469510
    [Abstract] [Full Text] [Related]

  • 26. No effect of dopamine depletion on the binding of the high-affinity D 2/3 radiotracer [11C]FLB 457 in the human cortex.
    Frankle WG, Mason NS, Rabiner EA, Ridler K, May MA, Asmonga D, Chen CM, Kendro S, Cooper TB, Mathis CA, Narendran R.
    Synapse; 2010 Dec 15; 64(12):879-85. PubMed ID: 20506387
    [Abstract] [Full Text] [Related]

  • 27. [18F]Fallypride PET measurement of striatal and extrastriatal dopamine D 2/3 receptor availability in recently abstinent alcoholics.
    Rominger A, Cumming P, Xiong G, Koller G, Böning G, Wulff M, Zwergal A, Förster S, Reilhac A, Munk O, Soyka M, Wängler B, Bartenstein P, la Fougère C, Pogarell O.
    Addict Biol; 2012 Mar 15; 17(2):490-503. PubMed ID: 22023291
    [Abstract] [Full Text] [Related]

  • 28. In vivo affinity of [18F]fallypride for striatal and extrastriatal dopamine D2 receptors in nonhuman primates.
    Slifstein M, Hwang DR, Huang Y, Guo N, Sudo Y, Narendran R, Talbot P, Laruelle M.
    Psychopharmacology (Berl); 2004 Sep 15; 175(3):274-86. PubMed ID: 15024551
    [Abstract] [Full Text] [Related]

  • 29. The interrelationship of dopamine D2-like receptor availability in striatal and extrastriatal brain regions in healthy humans: a principal component analysis of [18F]fallypride binding.
    Zald DH, Woodward ND, Cowan RL, Riccardi P, Ansari MS, Baldwin RM, Cowan RL, Smith CE, Hakyemez H, Li R, Kessler RM.
    Neuroimage; 2010 May 15; 51(1):53-62. PubMed ID: 20149883
    [Abstract] [Full Text] [Related]

  • 30. [18F]fallypride characterization of striatal and extrastriatal D2/3 receptors in Parkinson's disease.
    Stark AJ, Smith CT, Petersen KJ, Trujillo P, van Wouwe NC, Donahue MJ, Kessler RM, Deutch AY, Zald DH, Claassen DO.
    Neuroimage Clin; 2018 May 15; 18():433-442. PubMed ID: 29541577
    [Abstract] [Full Text] [Related]

  • 31. Optimized in vivo detection of dopamine release using 18F-fallypride PET.
    Ceccarini J, Vrieze E, Koole M, Muylle T, Bormans G, Claes S, Van Laere K.
    J Nucl Med; 2012 Oct 15; 53(10):1565-72. PubMed ID: 22933820
    [Abstract] [Full Text] [Related]

  • 32. In vivo imaging of dopamine receptors in a model of temporal lobe epilepsy.
    Yakushev IY, Dupont E, Buchholz HG, Tillmanns J, Debus F, Cumming P, Heimann A, Fellgiebel A, Luhmann HJ, Landvogt C, Werhahn KJ, Schreckenberger M, Potschka H, Bartenstein P.
    Epilepsia; 2010 Mar 15; 51(3):415-22. PubMed ID: 19694792
    [Abstract] [Full Text] [Related]

  • 33. Striatal and extrastriatal dopamine D2/D3 receptors in schizophrenia evaluated with [18F]fallypride positron emission tomography.
    Kegeles LS, Slifstein M, Xu X, Urban N, Thompson JL, Moadel T, Harkavy-Friedman JM, Gil R, Laruelle M, Abi-Dargham A.
    Biol Psychiatry; 2010 Oct 01; 68(7):634-41. PubMed ID: 20673873
    [Abstract] [Full Text] [Related]

  • 34. Effect of amphetamine on [(18)F]fallypride in vivo binding to D(2) receptors in striatal and extrastriatal regions of the primate brain: Single bolus and bolus plus constant infusion studies.
    Slifstein M, Narendran R, Hwang DR, Sudo Y, Talbot PS, Huang Y, Laruelle M.
    Synapse; 2004 Oct 01; 54(1):46-63. PubMed ID: 15300884
    [Abstract] [Full Text] [Related]

  • 35. Association of low striatal dopamine d2 receptor availability with nicotine dependence similar to that seen with other drugs of abuse.
    Fehr C, Yakushev I, Hohmann N, Buchholz HG, Landvogt C, Deckers H, Eberhardt A, Kläger M, Smolka MN, Scheurich A, Dielentheis T, Schmidt LG, Rösch F, Bartenstein P, Gründer G, Schreckenberger M.
    Am J Psychiatry; 2008 Apr 01; 165(4):507-14. PubMed ID: 18316420
    [Abstract] [Full Text] [Related]

  • 36. Innately low D2 receptor availability is associated with high novelty-seeking and enhanced behavioural sensitization to amphetamine.
    Tournier BB, Steimer T, Millet P, Moulin-Sallanon M, Vallet P, Ibañez V, Ginovart N.
    Int J Neuropsychopharmacol; 2013 Sep 01; 16(8):1819-34. PubMed ID: 23574629
    [Abstract] [Full Text] [Related]

  • 37. Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria.
    Drevets WC, Gautier C, Price JC, Kupfer DJ, Kinahan PE, Grace AA, Price JL, Mathis CA.
    Biol Psychiatry; 2001 Jan 15; 49(2):81-96. PubMed ID: 11164755
    [Abstract] [Full Text] [Related]

  • 38. Measuring the in vivo binding parameters of [18F]-fallypride in monkeys using a PET multiple-injection protocol.
    Christian BT, Narayanan T, Shi B, Morris ED, Mantil J, Mukherjee J.
    J Cereb Blood Flow Metab; 2004 Mar 15; 24(3):309-22. PubMed ID: 15091112
    [Abstract] [Full Text] [Related]

  • 39. GBR12909 attenuates amphetamine-induced striatal dopamine release as measured by [(11)C]raclopride continuous infusion PET scans.
    Villemagne VL, Wong DF, Yokoi F, Stephane M, Rice KC, Matecka D, Clough DJ, Dannals RF, Rothman RB.
    Synapse; 1999 Sep 15; 33(4):268-73. PubMed ID: 10421707
    [Abstract] [Full Text] [Related]

  • 40. Dopaminergic network differences in human impulsivity.
    Buckholtz JW, Treadway MT, Cowan RL, Woodward ND, Li R, Ansari MS, Baldwin RM, Schwartzman AN, Shelby ES, Smith CE, Kessler RM, Zald DH.
    Science; 2010 Jul 30; 329(5991):532. PubMed ID: 20671181
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.